The IndiPharm Newswire
IndiPharm Opens New Clinical Development Headquarters in Mumbai, India - Recent significant growth compels IndiPharm to move to larger facility in India
RADNOR, PA, March 15 — IndiPharm, Inc.and its wholly owned subsidiary, IndiPharm (India) Pvt. Ltd. today announced the opening of IndiPharm’s new clinical research operational headquarters in Powai, Mumbai, India. The move is driven by rapid and significant growth of IndiPharm’s clinical operations team headed by Nigel McBean, VP & Director of Operations for IndiPharm. The new larger facility will support the significant expansion of IndiPharm’s core staff providing project management, clinical monitoring, data management, and QA services.
Since early 2007, IndiPharm has been providing full CRO clinical trial services in India. IndiPharm has expanded quickly in response to a rapidly growing client demand. The clinical research environment in India provides very attractive advantages for conducting quality clinical studies including large numbers of eligible patients, western trained, English speaking investigators, and lower costs.
"Our new location allows us to expand our core operations and strengthen our ability to deliver high quality clinical trials faster and at a lower cost in India. The new headquarters efficiently and comfortably accommodates our staff with the best available facilities and technologies," said Nigel McBean, Vice President and Director of Operations for IndiPharm (India) Pvt. Ltd.
"With this new expanded office space and growth in our clinical team, IndiPharm is well positioned to meet and exceed our client’s aggressive development milestones," commented Ed Brennan, President and CEO of IndiPharm, Inc.
About IndiPharm
IndiPharm is a U.S. based full service clinical research organization (CRO) providing Western pharmaceutical and biotechnology companies a full range of clinical trial services through its wholly owned subsidiary – IndiPharm (India) Pvt. Ltd. and its network of qualified physicians and scientists located in India, enabling those companies to conduct registration quality Phase I through IV clinical trials quicker and at a lower cost than is generally possible in the United States and other Western countries.
For more information, contact:
Nigel McBean, Vice President & Director of Operations
IndiPharm (India) Pvt. Ltd.
A-603, Delphi
Hiranandani Gardens
Powai, Mumbai 400076, INDIA
Tel :+91 22 4243 5800
nmcbean@indipharm.com
or
Michael Brown
Vice President, Business Development
IndiPharm, Inc
610-230-0153
mbrown@indipharm.com